136 related articles for article (PubMed ID: 35421635)
21. Role of salvage therapy in chemo resistant or recurrent high-risk gestational trophoblastic neoplasm.
Anantharaju AA; Pallavi VR; Bafna UD; Rathod PS; R VC; K S; Kundargi R
Int J Gynecol Cancer; 2019 Mar; 29(3):547-553. PubMed ID: 30700567
[TBL] [Abstract][Full Text] [Related]
22. EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis.
Alifrangis C; Agarwal R; Short D; Fisher RA; Sebire NJ; Harvey R; Savage PM; Seckl MJ
J Clin Oncol; 2013 Jan; 31(2):280-6. PubMed ID: 23233709
[TBL] [Abstract][Full Text] [Related]
23. Conservative Chemotherapy in Gestational Trophoblastic Disease: Experience With Etoposide, Methotrexate, and Dactinomycin Chemotherapy.
Byun SW; Park TC; Bae SN
Int J Gynecol Cancer; 2016 May; 26(4):790-5. PubMed ID: 27057813
[TBL] [Abstract][Full Text] [Related]
24. Real-world data of 14 cases of brain metastases from gestational trophoblastic neoplasia and a literature review.
Xiao P; Guo T; Luo Y; Zhang M; Yin R
Arch Gynecol Obstet; 2022 Apr; 305(4):929-935. PubMed ID: 34542678
[TBL] [Abstract][Full Text] [Related]
25. [Curative effects and influenced factors of EMA-CO as an initial regimen for the treatment of high-risk gestational trophoblastic neoplasia].
Liu W; Zhao W; Zhang YQ; Huang XF
Zhonghua Yi Xue Za Zhi; 2018 Dec; 98(47):3896-3899. PubMed ID: 30585038
[No Abstract] [Full Text] [Related]
26. EMA vs EMACO in the treatment of gestational trophoblastic neoplasia.
Jareemit N; Horowitz NS; Goldstein DP; Berkowitz RS; Elias KM
Gynecol Oncol; 2020 Jul; 158(1):99-104. PubMed ID: 32404247
[TBL] [Abstract][Full Text] [Related]
27. M-EA (methotrexate, etoposide, dactinomycin) and EMA-CO (methotrexate, etoposide, dactinomycin / cyclophosphamide, vincristine) regimens as first-line treatment of high-risk gestational trophoblastic neoplasia.
Singh K; Gillett S; Ireson J; Hills A; Tidy JA; Coleman RE; Hancock BW; Winter MC
Int J Cancer; 2021 May; 148(9):2335-2344. PubMed ID: 33210289
[TBL] [Abstract][Full Text] [Related]
28. Chemotherapy for gestational trophoblastic neoplasia patients with a FIGO score of 12 or greater: A multistudy analysis.
Li J; Yue H; Wang X; Chen R; Lu X
Eur J Obstet Gynecol Reprod Biol; 2019 Jul; 238():164-169. PubMed ID: 31136884
[TBL] [Abstract][Full Text] [Related]
29. Management and prognostic analysis of patients with gestational trophoblastic neoplasia (GTN) in FIGO stage IV and its special type.
Wang K; Chen Y
Clin Exp Metastasis; 2021 Feb; 38(1):47-59. PubMed ID: 33219408
[TBL] [Abstract][Full Text] [Related]
30. Clinical epidemiology and management of gestational trophoblastic neoplasia in Hungary in the past 34 years.
Fülöp V; Szigetvári I; Szepesi J; Végh G; Singh M; Berkowitz RS
J Reprod Med; 2012; 57(7-8):310-8. PubMed ID: 22838247
[TBL] [Abstract][Full Text] [Related]
31. Comparison of MACT and 5Fu+ACT-D chemotherapy regimens in the treatment of low-risk gestational trophoblastic neoplasia.
Wang Y; Miao JW; Wang T; Wang Y; Wu YM; Kong WM; Su L; Duan W
J Chemother; 2016 Apr; 28(2):135-9. PubMed ID: 27105436
[TBL] [Abstract][Full Text] [Related]
32. Results with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) chemotherapy in gestational trophoblastic neoplasia.
Turan T; Karacay O; Tulunay G; Boran N; Koc S; Bozok S; Kose MF
Int J Gynecol Cancer; 2006; 16(3):1432-8. PubMed ID: 16803542
[TBL] [Abstract][Full Text] [Related]
33. Actinomycin D, cisplatin, and etoposide regimen is associated with almost universal cure in patients with high-risk gestational trophoblastic neoplasia.
Even C; Pautier P; Duvillard P; Floquet A; Kerbrat P; Troalen F; Rey A; Balleyguier C; Tazi Y; Leary A; Augereau P; Morice P; Droz JP; Fizazi K; Lhommé C
Eur J Cancer; 2014 Aug; 50(12):2082-9. PubMed ID: 24910417
[TBL] [Abstract][Full Text] [Related]
34. Comparison of treatment for low-risk GTN with standard 8-day MTX/FA regimen versus modified MTX/FA regimen without chemotherapy on the weekend.
Braga A; de Souza Hartung Araújo C; Mora PAR; Paulino E; de Melo AC; Velarde GC; Dos Santos Esteves APV; Junior JA; Filho JR; Elias KM; Horowitz NS; Berkowitz RS
Gynecol Oncol; 2020 Mar; 156(3):598-605. PubMed ID: 31928806
[TBL] [Abstract][Full Text] [Related]
35. Management and risk factors of recurrent gestational trophoblastic neoplasia: An update from 2004 to 2017.
Kong Y; Zong L; Cheng H; Jiang F; Wan X; Feng F; Ren T; Zhao J; Yang J; Xiang Y
Cancer Med; 2020 Apr; 9(7):2590-2599. PubMed ID: 32022487
[TBL] [Abstract][Full Text] [Related]
36. Comparing cisplatin-based combination chemotherapy with EMA/CO chemotherapy for the treatment of high risk gestational trophoblastic neoplasia.
Lybol C; Thomas CM; Blanken EA; Sweep FC; Verheijen RH; Westermann AM; Boere IA; Reyners AK; Massuger LF; van Hoesel RQ; Ottevanger PB
Eur J Cancer; 2013 Mar; 49(4):860-7. PubMed ID: 23099004
[TBL] [Abstract][Full Text] [Related]
37. [Clinical analysis of patients with relapsed and chemo-resistant gestational trophoblastic neoplasia].
Zhou Y; Feng FZ; Xiang Y; Wan XR
Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):804-7. PubMed ID: 21211275
[TBL] [Abstract][Full Text] [Related]
38. EP-EMA regimen (etoposide and cisplatin with etoposide, methotrexate, and dactinomycin) in a series of 18 women with gestational trophoblastic neoplasia.
Han SN; Amant F; Leunen K; Devi UK; Neven P; Vergote I
Int J Gynecol Cancer; 2012 Jun; 22(5):875-80. PubMed ID: 22635033
[TBL] [Abstract][Full Text] [Related]
39. Real-World Study of Cisplatin, Etoposide, and Bleomycin Chemotherapy Regimen in Gestational Trophoblastic Neoplasia.
Wang M; Shen L; Xu X; Duan W; Miao J; Kong W; Su L; Wu Y
Biomed Res Int; 2021; 2021():6661698. PubMed ID: 34258277
[TBL] [Abstract][Full Text] [Related]
40. Outcomes for relapsed versus resistant low risk gestational trophoblastic neoplasia following single-agent chemotherapy.
Jareemit N; Horowitz NS; Goldstein DP; Berkowitz RS; Elias KM
Gynecol Oncol; 2020 Dec; 159(3):751-757. PubMed ID: 33023756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
